Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms

Haematologica

Volumn 98, Issue 9, 2013, Pages 1414-1420

  Pérez, Cristina ^a   Pascual, Marien ^a   Martín Subero, José Ignacio ^b   Bellosillo, Beatriz ^c   Segura, Victor ^a   Delabesse, Eric ^d   Álvarez, Sara ^e   Larrayoz, María José ^f   Rifón, José ^g   Cigudosa, Juan Cruz ^e   Besses, Carles ^c   Calasanz, María José ^f   Cross, Nicholas C P ^h   Prósper, Felipe ^a,g   Agirre, Xabier ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d UNIVERSITÉ PAUL SABATIER   (France)

^e Structural Biology and Biocomputing Programme   (Spain)

^f UNIVERSITY OF NAVARRA   (Spain)

^g UNIVERSITY CLINIC OF NAVARRA   (Spain)

^h UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 23; INTERLEUKIN 27; JANUS KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLUSTER ANALYSIS; CONTROLLED STUDY; DNA METHYLATION; DNA MICROARRAY; GENE MUTATION; GENE REGULATORY NETWORK; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NUCLEOTIDE SEQUENCE; POLYCYTHEMIA VERA; THROMBOCYTHEMIA;

CHRONIC DISEASE; DNA METHYLATION; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HUMANS; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS;

EID: 84883623144     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.084160     Document Type: Article

References (15)

1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
2. Thapaliya P, Tefferi A, Pardanani A, Steensma DP, Camoriano J, Wu W, et al. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. Am J Hematol. 2011;86(1):96-8.
3. Mesa RA, Hanson CA, Rajkumar SV, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood. 2000;96(10):3374-80.
4. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWGMRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood.115(9):1703-8.
5. Bevacizumab package leaflet. Available from: www.medicine.org
6. Barosi G, Bordessoule D, Briere J, Cervantes F, Demory JL, Dupriez B, et al. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European myelofibrosis network (EUMNET). Blood. 2005;106(8):2849-53.
7. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006;108(5):1497-503.
8. Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68-76.
9. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009;33(9):1199-203.
10. Pardanani A, Finke C, Abdelrahman RA, Lasho TL, Tefferi A. Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis. Am J Hematol. 2013;88(4):312-6.
11. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366 (9):799-807.
12. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-98.
13. Thapaliya P, Tefferi A, Pardanani A, Steensma DP, Camoriano J, Wu W, et al. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. Am J Hematol. 2011;86(1):96-8.
14. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112(8): 3065-72.
15. Silver RT, Vandris K, Goldman JJ. Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood. 2011;117(24): 6669-72.